Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972446 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
A Phase 2 study of Rheumatoid Arthritis, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06972446: Recruiting Phase 2 study of Rheumatoid Arthritis, sponsored by AbbVie.
NCT06972446 is a Phase 2 study of Rheumatoid Arthritis that is actively recruiting participants, run by AbbVie. The registered enrollment target is 180 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06972446, a Phase 2 study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA). This study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Primary Outcome
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lutikizumab
- DRUG Ravagalimab
Study Locations (20)
Florida
- Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 272298 - Avon Park
- Clinical Research Of West Florida - Phase I Unit /ID# 272428 - Clearwater
- Neoclinical Research - Hialeah /ID# 272070 - Hialeah
- South Florida Rheumatology /ID# 278339 - Hollywood
- Swati Shah, MD Rheumatology /ID# 273624 - Jacksonville
- Life Clinical Trials /ID# 272589 - Margate
- HMD Research LLC /ID# 272432 - Orlando
- Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 272755 - Tampa
California
- Private Practice - Dr. David S. Hallegua /ID# 277608 - Beverly Hills
- Advanced Clinical Research Center, LLC dba TriWest Research Associates /ID# 277826 - Chula Vista
- Newport Huntington Medical Group /ID# 272439 - Huntington Beach
- Cohen Medical Centers /ID# 278341 - Thousand Oaks
- The Lundquist Institute /ID# 272481 - Torrance
- Inland Rheumatology & Osteoporosis Medical Group /ID# 272449 - Upland
Illinois
- Deerbrook Medical Associates /ID# 273439 - Libertyville
- Willow Rheumatology and Wellness, PLLC /ID# 272691 - Willowbrook
Arizona
- Sun Valley Arthritis Center /ID# 278331 - Peoria
Colorado
- Tekton Research - Fort Collins - East Harmony Road /ID# 272472 - Fort Collins
Louisiana
- Accurate Clinical Research (SMO/Network/Consortium) /ID# 272650 - Lake Charles
Michigan
- AA Medical Research Center - Grand Blanc /ID# 272496 - Grand Blanc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT06972446 shows while recruiting
NCT06972446 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06972446 names 20 study sites across 7 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06972446 about?
NCT06972446 is a clinical study titled "A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis". Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA)...
What is the current status of trial NCT06972446?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-06-20. Estimated completion is 2027-11.
What conditions does trial NCT06972446 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06972446?
The interventions under investigation include: Placebo (DRUG), Lutikizumab (DRUG), Ravagalimab (DRUG).
Who is sponsoring clinical trial NCT06972446?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06972446 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06972446's enrollment target sits among peer trials
180 91st of 197 higher than 107 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI